108 related articles for article (PubMed ID: 10584502)
1. [The administration of Docetaxel (taxoter): a new stage in chemotherapy of cancer].
Evtushenko OI
Klin Khir; 1999; (8):48-52. PubMed ID: 10584502
[No Abstract] [Full Text] [Related]
2. In the clinic: where paclitaxel and docetaxel stand.
McNeil C
J Natl Cancer Inst; 1995 Aug; 87(15):1107. PubMed ID: 7674312
[No Abstract] [Full Text] [Related]
3. Docetaxel (Taxotere): a new anti-cancer drug with promising potential?
Verweij J
Br J Cancer; 1994 Aug; 70(2):183-4. PubMed ID: 7914419
[No Abstract] [Full Text] [Related]
4. Role of taxanes in adjuvant therapy.
Münster PN; Hudis CA
Cancer Invest; 2000; 18(1):32-8. PubMed ID: 10701365
[No Abstract] [Full Text] [Related]
5. Docetaxel: assessing a range of activity.
Aapro M; Rowinsky E
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S1-3. PubMed ID: 11340897
[No Abstract] [Full Text] [Related]
6. Clinical trials referral resource. Clinical trials with Docetaxel (Taxotere).
Cheson BD; Arbuck SG; Phillips PH
Oncology (Williston Park); 1993 Sep; 7(9):51-2. PubMed ID: 8105859
[No Abstract] [Full Text] [Related]
7. Taxoids: a new class of cytotoxic agents.
Marty M; Extra JM; Giacchetti S; Cuvier C; Espie M
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S25-8. PubMed ID: 7909941
[TBL] [Abstract][Full Text] [Related]
8. Taxing the taxanes: overused or undersold?
Miller M
J Natl Cancer Inst; 1999 Dec; 91(24):2077-8. PubMed ID: 10601377
[No Abstract] [Full Text] [Related]
9. Taxoids: new weapons against cancer.
Nicolaou KC; Guy RK; Potier P
Sci Am; 1996 Jun; 274(6):94-8. PubMed ID: 8643952
[No Abstract] [Full Text] [Related]
10. [Taxanes: a breakthrough in cancer chemotherapy].
Inbar M; Merimsky O; Chaitchik S
Harefuah; 1997 Jul; 133(1-2):31-6. PubMed ID: 9332055
[No Abstract] [Full Text] [Related]
11. Docetaxel (taxotere, Rhone-Poulenc Rorer).
MacConnachie AM
Intensive Crit Care Nurs; 1997 Apr; 13(2):119-20. PubMed ID: 9180501
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel hypersensitivity reactions: a role for docetaxel substitution.
Lokich J; Anderson N
Ann Oncol; 1998 May; 9(5):573. PubMed ID: 9653501
[No Abstract] [Full Text] [Related]
13. The scientific rationale for developing taxoids.
Aapro M
Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Kris MG; Millward M
Semin Oncol; 1999 Jun; 26(3 Suppl 10):1-2. PubMed ID: 10437742
[No Abstract] [Full Text] [Related]
15. Weekly schedules of docetaxel.
Burris H
Semin Oncol; 1998 Dec; 25(6 Suppl 13):21-3. PubMed ID: 9865688
[TBL] [Abstract][Full Text] [Related]
16. The development of docetaxel (Taxotere) in non-small cell lung cancer.
Kris MG; Miller VA; Ng KK; Grant SC
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-1-S14-4. PubMed ID: 9335515
[No Abstract] [Full Text] [Related]
17. Docetaxel (Taxotere) for advanced breast cancer.
Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520
[No Abstract] [Full Text] [Related]
18. Taxanes in ovarian cancer treatment.
Seetalarom K; Kudelka AP; Verschraegen CF; Kavanagh JJ
Curr Opin Obstet Gynecol; 1997 Feb; 9(1):14-20. PubMed ID: 9090476
[TBL] [Abstract][Full Text] [Related]
19. An expanding role for docetaxel.
Hortobagyi G
Semin Oncol; 1998 Dec; 25(6 Suppl 13):1-3. PubMed ID: 9865684
[No Abstract] [Full Text] [Related]
20. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
